本帖最后由 maicon08 于 2023-4-28 15:12 编辑
4 ^" j% Y- E5 p3 I& O" q! @& S' K% R) L$ ?3 M
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。% s4 B$ f6 g0 k
( v! ^/ _# O8 a3 \- dhttps://www.163.com/dy/article/I3BTTPRD053438SI.html
6 C* D. u. L' T4 u% O, I8 u1 ]7 E
! t, i9 J+ R5 L1 Q, Q, z3 i! I
% C8 k% K! L8 R1 E. _在研疗法-免疫治疗! g: f) @ l- q* W' O
Developmental Therapeutics—Immunotherapy
- C/ T8 G) p9 h
. s' t& s* _; ~3 O4 k摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 5 G; X4 F( \$ |4 v$ ?% x# ?7 v2 v
在研疗法-分子靶向药物和肿瘤生物学
0 D# E' T' a9 \! B2 B* m, I+ f Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
# K+ v" f! y# x; |9 Y4 c' v摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心 $ c) F$ o" J8 W7 k& C9 F( y a
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 , J- q& l0 P } [% ~, A6 `
胃肠道肿瘤-结直肠癌和肛门癌
1 F1 t* d3 R3 v: I! f/ p2 e- B Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院
4 A6 E! X( m0 v1 v, R4 J5 l& V: R
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary 4 Z# d# Z2 k& w6 ]
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 - |( @$ `0 u& F* r& D. B
妇科肿瘤 Gynecologic Cancer
+ C. w# q: ^ u) s摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 " X" G- Z/ @0 i1 w, M
头颈肿瘤
( d( ^8 Q8 w% ~* I2 d4 R* l Head and Neck Cancer + m+ @/ S3 S, m0 Q2 @; P# o2 o
摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
/ o0 e) s/ z+ {
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 # N& P# k# H7 J9 b' d* u
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心
; A( I0 S8 s" h) S3 o# D# f
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia j0 l, e5 ^9 \! |% z' A
摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
6 S9 y3 l0 n1 O% d0 ~0 K0 k* B& R* D. O
血液系统恶性肿瘤-浆细胞疾病, L& U& M* p! q+ N
Hematologic Malignancies—Plasma Cell Dyscrasia 5 }' r, W( K0 ?
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 3 ]; [9 v7 l% |
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
- M" b7 f* i+ \ o) {& _3 Z. L Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
% A; x7 s& H/ R( |( P7 I5 E5 K摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
N% n* T7 m5 r* g i
肺癌-转移性非小细胞肺癌
- X* t" R# u- e% ]3 H' |+ I. j [ Lung Cancer—Non-Small Cell Metastatic
& i% P2 L. l4 }. A摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院 , L" x) T! Y- S" }" E
* H" ~* Q, o: L# l
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
4 R p2 q( y' J, D9 D
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 $ n" Z* E2 P3 M) L. {$ e' ~
黑色素瘤/皮肤癌
# u8 n4 s' R; w2 N) a Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 - ?0 u* `8 h1 q3 ~% l9 W
快速摘要报告
0 M- t/ U4 b9 ?. b! V. m Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
1 V2 X* E% V$ @; t( g% Y
临床科学研讨会" C% q- }" L0 ~" \& `4 f
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院 0 }5 k& [6 ?3 g v( r2 X! p" Q
$ I2 m/ P C4 M0 x: G! w5 N* y | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
